The human vasoactive intestinal peptide receptor: molecular identification by covalent cross-linking in colonic epithelium.

Couvineau A, Laburthe M

The Journal of clinical endocrinology and metabolism1 Jul 1985Cited by 56 (Europe PMC)

PMID2987295DOI10.1210/jcem-61-1-50PepBankPUB-02987295

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

7 results from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueMechanism
In human colonic epithelial membranes, labelled VIP formed three major complexes of 66,000, 33,000 and 16,000 mol wt.
In plain wordsIn lab tests on human colon membranes, labelled VIP attached to three protein complexes of different sizes.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableVIP-protein complexes on human colonic membranes
Study
humann: not reported in source
Human colonic epithelial membranes
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Sodium dodecyl sulfate-polyacrylamide gel autoradiographic studies of affinity labeled membranes revealed three major bands corresponding to [125I]VIP-protein complexes of 66,000, 33,000, and 16,000 mol wt.
1 context sentence(design, population, supporting numbers)
Summary · context
To characterize the molecular components of the vasoactive intestinal peptide (VIP) receptor in human intestine, [125I]VIP was covalently bound to human colonic epithelial membranes using dithio-bis(succinimidyl propionate).
Report a problemFND-0298729501
02LabEx vivo tissueMechanism
In human colonic membranes, VIP abolished labelling of the 66,000 and 33,000 mol wt complexes, so this labelling was specific; labelling of the 16,000 mol wt complex was not abolished.
In plain wordsIn lab tests on human colon membranes, VIP blocked the labelling of two of the three complexes, showing specific binding for those two.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableSpecificity of VIP labelling of the complexes
Study
humann: not reported in source
Human colonic epithelial membranes
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Labeling of the 66,000 and 33,000 mol wt complexes was specific, since it was abolished by VIP, while labeling of the 16,000 mol wt complex was not.
1 context sentence(design, population, supporting numbers)
Summary · context
To characterize the molecular components of the vasoactive intestinal peptide (VIP) receptor in human intestine, [125I]VIP was covalently bound to human colonic epithelial membranes using dithio-bis(succinimidyl propionate).
Report a problemFND-0298729502
03LabEx vivo tissueMechanism
In human colonic membranes, low VIP concentrations (10(-10) to 10(-8) M) inhibited labelling of the 66,000 mol wt complex; glucagon and octa-cholecystokinin had no effect.
In plain wordsIn lab tests on human colon membranes, low VIP doses blocked labelling of the largest complex, but glucagon and CCK-8 did not.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseInhibition of 66,000 mol wt labelling by VIP, glucagon and CCK-8
Study
humann: not reported in source
Human colonic epithelial membranes
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Densitometric scanning of autoradiographs indicated that labeling of the 66,000 mol wt complex was inhibited by low VIP concentrations in the 10(-10)-10(-8) M range, but was unaffected by glucagon or octa-cholecystokinin.
1 context sentence(design, population, supporting numbers)
Summary · context
To characterize the molecular components of the vasoactive intestinal peptide (VIP) receptor in human intestine, [125I]VIP was covalently bound to human colonic epithelial membranes using dithio-bis(succinimidyl propionate).
Report a problemFND-0298729503
04LabEx vivo tissueMechanism
In human colonic membranes, VIP-(2-28) reduced labelling of the 66,000 mol wt complex with a potency 1/100th that of VIP.
In plain wordsIn lab tests on human colon membranes, VIP blocked labelling about 100 times more strongly than the shortened fragment VIP-(2-28).
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreasePotency of VIP-(2-28) versus VIP at the 66,000 mol wt complex
Study
humann: not reported in source
Human colonic epithelial membranes
Comparator
VIP-(2-28)
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
It was also reduced by VIP-(2-28), with a potency 1/100th that of VIP
1 context sentence(design, population, supporting numbers)
Summary · context
To characterize the molecular components of the vasoactive intestinal peptide (VIP) receptor in human intestine, [125I]VIP was covalently bound to human colonic epithelial membranes using dithio-bis(succinimidyl propionate).
Report a problemFND-0298729504
05LabEx vivo tissueMechanism
In human colonic membranes, the 33,000 mol wt complex behaved like the 66,000 complex in specificity and GTP sensitivity, but it had lower affinity for VIP (labelling inhibited by 10(-9) to 10(-7) M VIP).
In plain wordsIn lab tests on human colon membranes, the middle-sized VIP-binding complex needed higher VIP doses to be blocked than the largest complex.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseInhibition of 33,000 mol wt labelling by native VIP
Study
humann: not reported in source
Human colonic epithelial membranes
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
The 33,000 mol wt complex behaved similarly to the 66,000 mol wt complex with respect to specificity and GTP sensitivity, but differed in one major feature, its affinity for VIP. Its labeling was inhibited by native VIP concentrations in the 10(-9)-10(-7) M range.
1 context sentence(design, population, supporting numbers)
Summary · context
To characterize the molecular components of the vasoactive intestinal peptide (VIP) receptor in human intestine, [125I]VIP was covalently bound to human colonic epithelial membranes using dithio-bis(succinimidyl propionate).
Report a problemFND-0298729506
06LabEx vivo tissueMechanism
In human colonic membranes, two proteins of 63,000 and 30,000 mol wt were identified as VIP-binding sites; the 63,000 protein fits the VIP receptor coupled to adenylate cyclase and the 30,000 protein is a low affinity binding site.
In plain wordsIn lab tests on human colon membranes, two proteins bound VIP: one fits the VIP receptor and the other binds VIP weakly.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableIdentity of VIP-binding proteins
Study
humann: not reported in source
Human colonic epithelial membranes
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Assuming one molecule of [125I]VIP bound per molecule of protein, two proteins of 63,000 and 30,000 mol wt were identified as VIP-binding sites. The 63,000 mol wt protein had the properties expected for the VIP receptor coupled to adenylate cyclase in human colon, while the 30,000 mol wt protein was…
1 context sentence(design, population, supporting numbers)
Summary · context
To characterize the molecular components of the vasoactive intestinal peptide (VIP) receptor in human intestine, [125I]VIP was covalently bound to human colonic epithelial membranes using dithio-bis(succinimidyl propionate).
Report a problemFND-0298729507
07LabEx vivo tissueMechanism
In human colonic membranes, dithiothreitol pretreatment strongly reduced [125I]VIP labelling of the two binding proteins, which does not support the 30,000 protein being a monomer of the high affinity site.
In plain wordsIn lab tests on human colon membranes, a reducing agent strongly lowered VIP labelling of both proteins.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseEffect of dithiothreitol on VIP labelling
Study
humann: not reported in source
Human colonic epithelial membranes
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Treatment of human colonic membranes with the sulfhydryl reducing agent dithiothreitol before [125I]VIP binding strongly reduced the labeling of the two proteins. This finding does not support the hypothesis that the low affinity 30,000 mol wt binding site may be a monomer of the high affinity binding site.
1 context sentence(design, population, supporting numbers)
Summary · context
To characterize the molecular components of the vasoactive intestinal peptide (VIP) receptor in human intestine, [125I]VIP was covalently bound to human colonic epithelial membranes using dithio-bis(succinimidyl propionate).
Report a problemFND-0298729508

Studies that did not test the peptide alone1

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

08LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueMechanism
In human colonic membranes, GTP at 10(-7) to 10(-3) M reduced [125I]VIP labelling of the 66,000 mol wt complex.
In plain wordsIn lab tests on human colon membranes, GTP reduced the labelling of the largest VIP-binding complex.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseEffect of GTP on 66,000 mol wt labelling
Study
humann: not reported in source
Human colonic epithelial membranes
Outcome group
Receptor activity and mechanism · Gastrointestinal
Source sentences
Summary
and by GTP in the concentration range of 10(-7)-10(-3) M.
1 context sentence(design, population, supporting numbers)
Summary · context
To characterize the molecular components of the vasoactive intestinal peptide (VIP) receptor in human intestine, [125I]VIP was covalently bound to human colonic epithelial membranes using dithio-bis(succinimidyl propionate).
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0298729505

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.